Loading
A phase 3 trial testing TQB2102 in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, now recruiting.
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer is a phase 3 interventional study registered as NCT07008976, led by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Open-label, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in Patients With HER2-positive Advanced Breast Cancer. Planned enrolment is 246 participants (estimated). The study started in 2025-07-07 and primary completion is expected in 2028-03. No results have been posted on ClinicalTrials.gov.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer.